|
Patent landscape, scope, and claims: |
Scope and claim coverage of US Patent 6,017,927 (quinuclidine derivative family) and the US patent landscape for clearance vs. generic or reformulation entry
US Patent 6,017,927 claims a broad chemical genus centered on quinuclidine derivatives defined by a Markush formula (I), with coverage extended to salts, N-oxides, and quaternary ammonium salts, plus a formulation claim to compositions comprising the claimed derivatives. The claims are structured to capture: (1) wide variation at “Ring A” (aryl/cycloalkyl/cycloalkenyl with substitution patterns), (2) variation at linker “X” (bond or methylene), (3) variation at “R” substituents, (4) integer parameters “l, m, n” within specified ranges, and (5) a limited set of specific exemplified compounds in claim 6.
Because the text provided contains only claim language and not the patent’s specification, the actual therapeutic target, compound numbering, experimental examples, prosecution history, or dependent claim dependency network beyond claims 1–7, a landscape that depends on those details cannot be produced completely and accurately.
What does US Patent 6,017,927 claim: the quinuclidine derivative formula I scope?
Core claim coverage (Claim 1) is a quinuclidine derivative of formula (I) defined by four variable components and range parameters, plus allowable derivative forms.
What is variable in formula (I)? (Ring A, X, R, l, m, n)
Below is the practical “design space” captured by Claim 1, using the claim’s own variable definitions.
Ring A
- Ring A is one of:
- aryl group with 6–14 carbons
- cycloalkyl with 3–8 carbons
- cycloalkenyl with 3–8 carbons
- Ring A may be substituted (unsubstituted or substituted) by one or more substituents selected from:
- halogen
- hydroxyl
- lower alkoxy
- carboxyl
- lower alkoxycarbonyl
- lower acyl
- mercapto / lower alkylthio
- sulfonyl / lower alkylsulfonyl / sulfinyl / lower alkylsulfinyl
- sulfonamido / lower alkanesulfonamido
- carbamoyl / thiocarbamoyl
- (mono-/di-) lower alkylcarbamoyl
- nitro / cyano
- amino / mono-/di-lower alkylamino
- methylenedioxy / ethylenedioxy
- lower alkyl optionally substituted by halogen, hydroxyl, lower alkoxyl, amino, or mono-/di-lower alkylamino
Interpretation for freedom-to-operate: Ring A is the main breadth driver. It can cover many aromatic and non-aromatic ring systems plus broad functionalization.
X (linker)
- X is either:
- a single bond, or
- a methylene group
This limits the immediate connectivity to one of two possibilities.
R (substituent)
- R is one group selected from the same broad set as used for Ring A substituents, including:
- halogen, hydroxyl, lower alkoxy, carboxyl, lower alkoxycarbonyl
- lower acyl, mercapto, lower alkylthio
- sulfonyl, lower alkylsulfonyl, sulfinyl, lower alkylsufinyl
- sulfonamido, lower alkanesulfonamido
- carbamoyl, thiocarbamoyl, (mono-/di-) lower alkylcarbamoyl
- nitro, cyano, amino, (mono-/di-) lower alkylamino
- methylenedioxy, ethylenedioxy
- lower alkyl optionally substituted (halogen, hydroxyl, lower alkoxyl, amino, mono-/di-lower alkylamino)
l, m, n (range parameters)
- l: 0 or 1
- m: 0 or 1–3
- n: 1 or 2
Even though Claim 1’s formula (I) is not fully rendered here, these parameters indicate controlled but nontrivial variability in the structure.
Allowable derivative forms
Claim 1 explicitly covers:
- a salt
- an N-oxide
- a quaternary ammonium salt
These are common “definitional expansions” in older small-molecule patent drafting and can matter for clearance if an investigator chooses a specific salt form or N-oxide.
Which dependent claims narrow US 6,017,927 to a smaller subset?
Claim 2 narrowing
Claim 2 limits Claim 1 by specifying:
- R is limited to:
- halogen, lower alkyl, hydroxyl, lower alkoxy, nitro, cyano, amino, mono-/di-lower alkylamino
- Ring A is limited to:
- aryl (6–14 carbons), cycloalkyl (3–8 carbons), cycloalkenyl (3–8 carbons)
- and clarifies that Ring A substitutions are limited to:
- halogen, lower alkyl, hydroxyl, lower alkoxyl, nitro, cyano, amino, mono-/di-lower alkylamino
So Claim 2 removes from Claim 1 many functional groups like carboxyl, acyl, sulfonyl/sulfinyl, carbamoyl/thiocarbamoyl, alkoxycarbonyl, and di-oxygenated methylenedioxy/ethylenedioxy, focusing on simpler electronics.
Claim 3 narrowing
- m is 0
- Ring A is restricted to aryl/cycloalkyl/cycloalkenyl substituted by:
- halogen, lower alkyl, hydroxyl, lower alkoxy
This further reduces substitution complexity.
Claim 4 narrowing
- Ring A is either:
- phenyl substituted by halogen or lower alkyl, or
- cycloalkyl
This is narrower and more practically useful for mapping if an accused compound sits within those ring patterns.
Claim 5 narrowing
- X is a single bond (as opposed to methylene).
Claim 6: concrete exemplified compounds
Claim 6 recites five specific named derivatives:
- 3-quinuclidinyl 1-phenyl-1,2,3,4-tetrahydro-2-isoquinolinecarboxylate
- 3-quinuclidinyl 1-(4-chlorophenyl)-1,2,3,4-tetrahydro-2-isoquinolinecarboxylate
- 3-quinuclidinyl 1-(4-fluorophenyl)-1,2,3,4-tetrahydro-2-isoquinolinecarboxylate
- 3-quinuclidinyl 1,2,3,4-tetrahydro-1-(4-tolyl)-2-isoquinolinecarboxylate
- 3-quinuclidinyl 1-cyclohexyl-1,2,3,4-tetrahydro-2-isoquinolinecarboxylate
This claim is important for two reasons:
- it provides a direct mapping target for freedom-to-operate if one of these is the marketed active or a close variant
- it creates a foothold that can support narrower interpretations in claim construction even when the genus is broad
Claim 7: composition/formulation coverage
Claim 7 is a pharmaceutical composition comprising:
- the quinuclidine derivative of formula (I) (with the same variable definitions as Claim 1)
- plus a pharmaceutically acceptable carrier
This is a classic formulation claim that can block:
- generic entry using the same active in the same formulation type, and
- attempts to “work around” by selecting a carrier or dosage form that still contains the claimed active.
How broad is the genus protection in US 6,017,927 vs. typical quinuclidine patents?
Relative breadth drivers in this patent:
- Ring A breadth: aryl 6–14 C, cycloalkyl 3–8 C, cycloalkenyl 3–8 C with “one or more” substituents from a long list.
- R breadth: the same long list for another substituent position.
- Multiple derivative forms: salts, N-oxides, quaternary ammonium salts.
- Two linker options: bond vs methylene.
Relative constraint drivers:
- X is binary (bond or methylene).
- l, m, n are constrained to small integer ranges.
- Dependent claims 2–5 carve out subsets with reduced substitution lists.
Net effect: Claim 1 is a large chemical space capture rather than a narrow compound-specific monopoly.
What is the likely scope of “design-around” for competitors?
Based on the claim language alone, an entrant trying to avoid literal infringement would typically need to move at least one of the following structural “decision points”:
- avoid Ring A structures within aryl 6–14 C, cycloalkyl 3–8, or cycloalkenyl 3–8
- avoid substitution patterns that fall within the permitted enumerated set for Ring A or R
- replace X so it is neither single bond nor methylene
- use parameter sets that are outside l ∈ {0,1}, m ∈ {0,1,2,3}, n ∈ {1,2}
- avoid a claimed derivative form (salt/N-oxide/quaternary ammonium) or use a different chemical form not captured by the claim’s definitional expansions (though the claim is explicit that these forms are included)
However, whether courts treat the permitted substituent lists as exhaustive (they appear exhaustive) and how they construe “lower” terms will depend on the specification and claim interpretation.
What formulations are protected by US 6,017,927 beyond the API?
Claim 7 is not limited to:
- a dosage form (tablet, capsule, injection, patch)
- a release profile (immediate, controlled)
- an excipient set
It requires only a pharmaceutically acceptable carrier. That means the patent’s formulation protection is content-based (contains the claimed compound) rather than process-based or carrier-specific.
Practical consequence: a generic that uses the same quinuclidine derivative as API in any pharmaceutically acceptable carrier is exposed under Claim 7, unless invalidated or avoided by changing the active’s structure outside Claim 1 scope.
What generic entry risks exist given Claim 7’s carrier-agnostic language?
If the marketed drug contains one of:
- compounds recited in Claim 6, or
- compounds that fit Claim 1’s formula variables
then a generic or reformulation product that keeps the same active structure can face infringement risk for both:
- the API (Claim 1–6)
- the composition (Claim 7)
Literal risk increases further if the generic uses the same salt form or quaternary ammonium salt targeted by Claim 1, or an N-oxide if used.
What patents protect the same quinuclidine chemical space around US 6,017,927?
A full US patent landscape requires at minimum:
- the patent’s assignee and priority data
- the underlying compound series identity (often tied to therapeutic target)
- related patent families with continuations/divisionals/foreign counterparts
- prosecution history and cited prior art
Those elements are not present in the prompt, and a landscape without them would not meet the “complete and accurate” standard.
Orange Book status, exclusivity timelines, and Paragraph IV risk: what is the regulatory posture of US 6,017,927?
Regulatory posture cannot be generated accurately from claim text alone because:
- Orange Book listings require the specific FDA-approved drug product and active ingredient name (including salt/ester form)
- 6,017,927 may or may not be listed for a particular NDA/ANDA
- exclusivity and patent-expiration mapping requires the Orange Book Patent–Product–Exclusivity data and associated expiration dates
No such FDA/Orange Book identifiers are provided in the prompt.
Key Takeaways
- US 6,017,927 Claim 1 broadly covers a quinuclidine derivative genus defined by formula (I) with wide latitude at Ring A (aryl/cycloalkyl/cycloalkenyl; 6–14, 3–8 carbons) and R (multi-functional enumerated substituent set), limited by X (bond or methylene) and integer parameters l, m, n.
- Coverage extends to salts, N-oxides, and quaternary ammonium salts.
- Dependent claims narrow substitution sets (Claims 2–5) and lock in specific named compounds (Claim 6).
- Claim 7 provides broad composition coverage: any pharmaceutical composition containing the claimed quinuclidine derivative plus a pharmaceutically acceptable carrier.
FAQs
Does US 6,017,927 cover quaternary ammonium salts and N-oxides?
Yes. Claim 1 explicitly includes salts, N-oxides, and quaternary ammonium salts of the quinuclidine derivatives.
What structural element is most constrained by US 6,017,927?
The linker X is constrained to either a single bond or methylene.
Which claim includes specifically named compounds rather than only a Markush genus?
Claim 6 recites five named quinuclidinyl tetrahydro-isoquinolinecarboxylates.
Is pharmaceutical composition coverage limited to a particular dosage form in US 6,017,927?
No. Claim 7 requires only a pharmaceutically acceptable carrier, not a particular formulation type.
Can a competitor avoid infringement by changing only the salt form?
Claim 1 already covers salts and quaternary ammonium salts, so switching between covered salt/quaternary forms does not avoid the claim if the underlying derivative falls within formula (I).
References
No references are included because the prompt provides only claim text and not bibliographic or source identifiers needed for compliant inline citation.
More… ↓
⤷ Start Trial
|
